

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMBER, 2006

(Rs.in Lakhs)

		STAND ALONE					CONSOLIDATED		
	Particulars	Quarter ended 31.12.2006	Quarter ended 31.12.2005	9 Months ended 31.12.2006	9 Months ended 31.12.2005	Audited for the Year Ended 31.03.2006	Quarter ended 31.12.2006	9 Months ended 31.12.2006	Audited for the Year Ended 31.03.2006
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1	Net Sales/Income from operations (Net of Excise Duty)	14962	10798	47183	25402	38111	14951	47192	38111
2	Other Income	245	216	1021	804	1063	227	1009	1062
3	<u>Total Income:</u>	15207	11014	48204	26206	39174	15178	48201	39173
4	<u>Expenditure:</u>								
	a. (Increase) / Decrease in Stock	737	1160	2105	(1583)	(1310)	852	2105	(1310)
	b. Consumption of Raw Material	5956	4042	21239	12442	18292	5797	21213	18292
	c. Staff Cost	1316	424	3308	1213	1820	1415	3618	1874
	d. Other Expenditure								
	- Manufacturing Expenses	1116	842	3009	2469	3317	1116	3010	3317
	- Other expenses	1583	1220	4312	3072	4324	1672	4520	4392
5	Finance charges	381	136	651	344	558	381	652	558
6	Depreciation	587	370	1429	1096	1482	588	1430	1482
7	Total Expenses:	11676	8194	36053	19052	28483	11821	36548	28605
8	Profit Before Tax (3-7)	3531	2820	12151	7154	10691	3357	11653	10568
9	Provision for Taxation								
	- Current Tax	(23)	881	2787	2292	3316	(23)	2787	3316
	- Deferred Tax	272	44	272	94	313	232	157	284
	- Fringe Benefit Tax	9	5	16	10	15	9	16	15
10	Profit After Tax: (8-9)	3273	1890	9076	4758	7047	3139	8693	6953
11	Paid-up Equity Share Capital (Face Value : Rs.10 per share)	1282	1282	1282	1282	1282	1282	1282	1282

12	Reserves excluding revaluation reserves					32800			32706
13	Earnings Per Share								
	- Basic (Rs.)	25.54	14.74	70.80	37.12	54.98	24.49	67.81	54.24
	- Diluted (Rs.)	25.06	14.74	69.47	37.12	53.94	24.03	66.54	53.22
14	Aggregate of non-promoter shareholding								
	- No. of shares	5905700	5898459	5905700	5898459	5898259	5905700	5905700	5898259
	- Percentage of shareholding	46.07%	46.01%	46.07%	46.01%	46.01%	46.07%	46.07%	46.01%

NOTES:

1. The above results for the quarter and period ended 31st December, 2006, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 27th January, 2007.
2. The Consolidated results include the financials of subsidiaries, Divis Laboratories (USA) Inc., and Divi's Laboratories Europe AG.
3. As there are no subsidiaries required to be consolidated as on 31.12.2005, previous year figures are not given.
4. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly, there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
5. The company has charged an amount of Rs. 1822 lakhs towards Employee Compensation Expense for the 9-month period during the current year on account of stock options granted to eligible employees.
6. The results of the current quarter include operations from the SEZ Unit at Chippada, Bheemunipatnam.
7. The company had a successful inspection by the US-FDA, without any observations, for its EOU and SEZ Units at village Chippada, Bheemunipatnam Mandal near Visakhapatnam during November, 2006. The purpose of this inspection was for product pre-approval and general cGMP (Current Good Manufacturing Practices).
8. The figures for the previous period have been regrouped, wherever necessary.
9. Information on Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31st December, 2006:

Pending as at 01-10-2006	Received	Disposal	Lying unresolved as at 31-12-2006
0	9	9	0

for Divi's Laboratories Limited

Hyderabad
27.01.2007

Dr. Murali K. Divi
Chairman & Managing Director